EcoDrugPlus

Solute Carrier Family 6 Member 9

Ensembl ID : ENSATEG00000008827
Gene Symbol: SLC6A9
2 Cross references
207 Possible Orthologues:

Solute Carrier Family 9 Member A3, Tandem Duplicate 1

Ensembl ID : ENSATEG00000005243
Gene Symbol: SLC9A3.1
3 Cross references
237 Possible Orthologues:

Somatostatin Receptor 2a

Ensembl ID : ENSATEG00000027370
Gene Symbol: SSTR2A
2 Cross references
192 Possible Orthologues:

Somatostatin Receptor Type 2-Like

Ensembl ID : ENSATEG00000024246
Gene Symbol: LOC113160025
2 Cross references
192 Possible Orthologues:

Somatostatin Receptor Type 5

Ensembl ID : ENSATEG00000002774
Gene Symbol: LOC113162615
2 Cross references
184 Possible Orthologues:

Sphingosine Kinase 2

Ensembl ID : ENSATEG00000022881
Gene Symbol: SPHK2
2 Cross references
202 Possible Orthologues:

Spleen Tyrosine Kinase

Ensembl ID : ENSATEG00000010626
Gene Symbol: SYK
3 Cross references
203 Possible Orthologues:

Steroid 17-Alpha-Hydroxylase/17,20 Lyase

Ensembl ID : ENSATEG00000006671
Gene Symbol: LOC113158084
3 Cross references
211 Possible Orthologues:

Steroid-5-Alpha-Reductase, Alpha Polypeptide 2a

Ensembl ID : ENSATEG00000015742
Gene Symbol: SRD5A2A
1 Cross references
208 Possible Orthologues:

Steroid-5-Alpha-Reductase, Alpha Polypeptide 2b

Ensembl ID : ENSATEG00000016286
Gene Symbol: SRD5A2B
1 Cross references
192 Possible Orthologues:

Sterol O-Acyltransferase 1

Ensembl ID : ENSATEG00000006879
Gene Symbol: SOAT1
3 Cross references
211 Possible Orthologues:

Tachykinin Receptor 1a

Ensembl ID : ENSATEG00000013036
Gene Symbol: TACR1A
2 Cross references
214 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).